News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
Dec 09, 2021
Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal CarcinomatosisDec 07, 2021
Clover Signs COVID-19 Vaccine Supply Agreement with UNICEFNov 26, 2021
Clover's COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical TrialNov 18, 2021
Clover and CEPI Expand Partnership for COVID-19 Vaccine Candidate to Include Evaluation as a BoosterNov 04, 2021
Clover Biopharmaceuticals Announces Offer Price and Allotment Results of the Global OfferingSep 22, 2021
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and InterestSep 10, 2021
Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 VaccineJul 06, 2021
Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine CandidateJun 30, 2021
Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover's COVID-19 Vaccine for the COVAX FacilityJun 30, 2021
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate
